Off-label prescriptions in diabetic foot
Prescrições off-label em pé diabético
Luís Jesuíno de Oliveira Andrade; Larissa Santos França; Paulo Roberto Santana de Melo; Marcelo Araújo
Abstract
Keywords
Resumo
Palavras-chave
References
Emmerich J, Dumarcet N, Lorence A. France's new framework for regulating off-label drug use. N Engl J Med. 2012;367(14):1279-81.
Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-9.
Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8.
Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-90.
Griffis CD, Metcalfe S, Bowling FL, Boulton AJ, Armstrong DG. The use of gentamycin-impregnated foam in the management of diabetic foot infections: a promising delivery system?. Expert Opin Drug Deliv. 2009;6(6):639-42.
Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med. 2006;23(4):348-59.
Lipsky BA, Kuss M, Edmonds M, Reyzelman A, Sigal F. Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. J Am Podiatr Med Assoc. 2012;102(3):223-32.
Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet. 2005;366(9498):1725-35.
Lo Pardo D, Pezzuti G, Selleri C, Pepe S, Esposito S. Adjuvant treatment of diabetic foot. Infez Med. 2012;20(^sSuppl 1):35-41.
Holmes C, Wrobel JS, Maceachern MP, Boles BR. Collagenbased wound dressings for the treatment of diabetes-related foot ulcers: a systematic review. Diabetes Metab Syndr Obes. 2013;6:17-29.
Papanas N, Maltezos E. Cilostazol in diabetic neuropathy: premature farewell or new beginning?. Angiology. 2011;62(8):605-8.
Solerte SB, Fioravanti M, Cerutti N. Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications. Acta Diabetol. 1997;34(2):67-74.
Cicco G, Giorgino F, Cicco S. Wound healing in diabetes: hemorheological and microcirculatory aspects. Adv Exp Med Biol. 2011;701:263-9.
Baldwin DS, Kosky N. Off-label prescribing in psychiatric practice. Adv Psychiatr Treat. 2007;13(6):414-22.
Lowe-Ponsford FL, Baldwin DS. Off-label prescribing by psychiatrists. Psychiatr Bull. 2000;24(11):415-7.
Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8.
Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-6.
Resolução RDC n° 47, de 08 de setembro de 2009. 2009:31.
Blanes JI. Consensus document on treatment of infections in diabetic foot. Rev Esp Quimioter. 2011;24(4):233-62.
Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719-24.